Mestag harnesses new insights into fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory diseases. We are progressing a unique pipeline of novel antibodies designed to direct and drive the immune system using known and emerging fibroblast-immune biology.
Mestag Therapeutics
Mestag Therapeutics
- Life Sciences
- Cambridge, United Kingdom
- £30m
- mestagtherapeutics.com
- Update Information
More venture news
- 19 Jun 2026
Houdini BioHoudini Bio launches with a £1.5m pre-seed led by SCVC to tackle gene silencing with machine learning DNA design platform
Pre-seedLife Sciences - 3 Jun 2026
ApohaApoha unlocks £27m in funding led by Singular to measure how molecules and materials behave under real-world conditions
EquityLife Sciences - 2 Jun 2026
IMU BiosciencesIMU Biosciences unlocks £40m Series A led by IQ Capital and Molten Ventures to decode the immune system with high-resolution blood analysis
Series ALife Sciences
